Bull
$0.57
Szenariopreis
$0.422
-0.042 (-9.87%)Zum Schluss
NewGenIVF Group Limited is a diversified healthcare and technology-driven platform focused on investments across fertility services, consumer wellness, digital assets, and real estate. The Company operates through three business divisions, which include NewGenProperty, which operates real estate development projects in the United Arab Emirates (UAE)'s Ras Al Khaimah Emirate; NewGenDigital, which serves as the Company's digital asset and decentralized finance (DeFi) solutions arm, and NewGenSup, which focuses on health and longevity products and solutions. Its legacy business involves providing in-vitro fertilization (IVF) and assisted reproductive treatment services, such as surrogacy and egg freezing across Asia.
NIVF is not a good buy right now due to its significant price decline and poor financial performance. The current price is $0.42, with a year-to-date change of -98.25%, indicating severe underperformance. Additionally, the RSI is at 25.414, suggesting the stock is oversold but may not rebound soon given the negative trends in revenue and net income.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

NewGenIVF Completes Convertible Note Exchange Agreement

NewGen's Investment in K25.ai Shows Significant Appreciation

NewGen Acquires Additional 3% Stake in K25.ai, Raising Ownership to 13%

NewGenIVF Acquires Additional Stake in K25.ai

NewGenIVF Acquires Additional Stake in K25.ai
NewGenIVF Group Limited is a diversified healthcare and technology-driven platform focused on investments across fertility services, consumer wellness, digital assets, and real estate. The Company operates through three business divisions, which include NewGenProperty, which operates real estate development projects in the United Arab Emirates (UAE)'s Ras Al Khaimah Emirate; NewGenDigital, which serves as the Company's digital asset and decentralized finance (DeFi) solutions arm, and NewGenSup, which focuses on health and longevity products and solutions. Its legacy business involves providing in-vitro fertilization (IVF) and assisted reproductive treatment services, such as surrogacy and egg freezing across Asia. It operates in the Healthcare sector.
NIVF is not a good buy right now due to its significant price decline and poor financial performance. The current price is $0.42, with a year-to-date change of -98.25%, indicating severe underperformance. Additionally, the RSI is at 25.414, suggesting the stock is oversold but may not rebound soon given the negative trends in revenue and net income.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.